Guggenheim analyst Seamus Fernandez initiated coverage of Mineralys Therapeutics with a Buy rating and $32 price target.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MLYS:
- Mineralys Therapeutics initiated with a Buy at Stifel
- Mineralys Therapeutics presents data from Phase 2 Target-HTN trial
- Mineralys Therapeutics Presents Positive Lorundrostat Results from the Phase 2 Target-HTN Trial at ACC.23/WCC
- Mineralys Therapeutics to Announce Fourth Quarter 2022 Financial Results and Host Conference Call on Wednesday, March 15, 2023
- Mineralys Therapeutics Abstracts Selected to be Presented at the American College of Cardiology Annual Scientific Session & Expo Together with the World Congress of Cardiology (ACC.23/WCC) in March 2023